Monopar Therapeutics (NASDAQ:MNPR) just reported results for the fourth quarter of 2023.
- Monopar Therapeutics reported earnings per share of -12 cents. This was above the analyst estimate for EPS of -15 cents.
- The company did not report any revenue for the quarter.